Annexon registers Phase 3 extension study of vonaprument for geographic atrophy

Annexon's registry activity for the week centers on a single new Phase 3 trial listing tied to its dry AMD program.

• **Vonaprument (ANX007), Phase 3, dry AMD with geographic atrophy:** Annexon registered "AiiM OLE" (NCT07807969), a study whose primary purpose is to assess the long term safety of intravitreal injections of vonaprument¹. The trial is not yet recruiting, with an estimated enrollment of 605 participants¹ who will receive vonaprument IVT injections every month for 24 months¹. Eligible participants are those who had a diagnosis of dry AMD with GA, finished the Phase 3 "ARCHER II" study (NCT06510816), and had not permanently stopped their assigned masked treatment by or before the ARCHER II Month 24 visit¹. The study's estimated start date is September 30, 2026, and it lists seven sites in the United States.